Rispens T - Search Results

1

Cross-Reactivity of Antibodies to Rituximab with Other Therapeutic Anti-CD20 Antibodies.

Rispens T, Kuijpers TW, Killestein J, van Kempen ZLE, Bloem K. Rispens T, et al. J Immunol. 2024 Feb 15;212(4):529-533. doi: 10.4049/jimmunol.2300647. J Immunol. 2024. PMID: 38149924

2

Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody.

Rispens T, Leeuwen Av, Vennegoor A, Killestein J, Aalberse RC, Wolbink GJ, Aarden LA. Rispens T, et al. Anal Biochem. 2011 Apr 15;411(2):271-6. doi: 10.1016/j.ab.2011.01.001. Epub 2011 Jan 7. Anal Biochem. 2011. PMID: 21216215

3

Differential effect of drug interference in immunogenicity assays.

Hart MH, de Vrieze H, Wouters D, Wolbink GJ, Killestein J, de Groot ER, Aarden LA, Rispens T. Hart MH, et al. Among authors: rispens t. J Immunol Methods. 2011 Sep 30;372(1-2):196-203. doi: 10.1016/j.jim.2011.07.019. Epub 2011 Jul 29. J Immunol Methods. 2011. PMID: 21824477

4

Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped.

Rispens T, Vennegoor A, Wolbink GJ, Polman CH, Killestein J. Rispens T, et al. Mult Scler. 2012 Jun;18(6):899-901. doi: 10.1177/1352458511431073. Epub 2011 Dec 19. Mult Scler. 2012. PMID: 22183929

5

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.

Vennegoor A, Rispens T, Strijbis EM, Seewann A, Uitdehaag BM, Balk LJ, Barkhof F, Polman CH, Wolbink G, Killestein J. Vennegoor A, et al. Among authors: rispens t. Mult Scler. 2013 Apr;19(5):593-600. doi: 10.1177/1352458512460604. Epub 2012 Sep 19. Mult Scler. 2013. PMID: 22992450

6

Drug interference in immunogenicity assays depends on valency.

Rispens T, Hart MH, Ooijevaar-de Heer P, van Leeuwen A, Vennegoor A, Killestein J, Wolbink GJ, van der Kleij D. Rispens T, et al. J Pharm Biomed Anal. 2013 Nov;85:179-85. doi: 10.1016/j.jpba.2013.07.022. Epub 2013 Jul 30. J Pharm Biomed Anal. 2013. PMID: 23954437

7

Haplotypes of FcγRIIa and FcγRIIIb polymorphic variants influence IgG-mediated responses in neutrophils.

van der Heijden J, Nagelkerke S, Zhao X, Geissler J, Rispens T, van den Berg TK, Kuijpers TW. van der Heijden J, et al. Among authors: rispens t. J Immunol. 2014 Mar 15;192(6):2715-21. doi: 10.4049/jimmunol.1203570. Epub 2014 Feb 19. J Immunol. 2014. PMID: 24554771

8

Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.

Vennegoor A, Rispens T, Van Oosten BW, Wattjes MP, Wondergem MJ, Teunissen CE, Van der Kleij D, Uitdehaag BM, Polman CH, Killestein J. Vennegoor A, et al. Among authors: rispens t. Mult Scler. 2015 Apr;21(4):481-4. doi: 10.1177/1352458514541507. Epub 2014 Jul 30. Mult Scler. 2015. PMID: 25078275

9

Inhibition of FcγR-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and FcγRIIb in human macrophages.

Nagelkerke SQ, Dekkers G, Kustiawan I, van de Bovenkamp FS, Geissler J, Plomp R, Wuhrer M, Vidarsson G, Rispens T, van den Berg TK, Kuijpers TW. Nagelkerke SQ, et al. Among authors: rispens t. Blood. 2014 Dec 11;124(25):3709-18. doi: 10.1182/blood-2014-05-576835. Epub 2014 Oct 28. Blood. 2014. PMID: 25352126 Free article.

10

Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients.

Bloem K, van Leeuwen A, Verbeek G, Nurmohamed MT, Wolbink GJ, van der Kleij D, Rispens T. Bloem K, et al. Among authors: rispens t. J Immunol Methods. 2015 Mar;418:29-38. doi: 10.1016/j.jim.2015.01.007. Epub 2015 Jan 27. J Immunol Methods. 2015. PMID: 25637408

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

304 results

Search Page

Filters